Sit Investment Associates’s Novo Nordisk NVO Stock Holding History

Sit Investment Associates’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-24,650	Closed	-$1.25M	–	529
2025 Q4	$1.25M	Hold	24,650	–	–	0.02%	358
2025 Q3	$1.37M	Sell	24,650 -290	-1%	-$17K	0.03%	343
2025 Q2	$1.72M	Sell	24,940 -49,715	-67%	-$3.38M	0.04%	329
2025 Q1	$5.18M	Buy	74,655 +6,547	+10%	+$541K	0.12%	187
2024 Q4	$5.86M	Sell	68,108 -28,940	-30%	-$3.13M	0.13%	187
2024 Q3	$11.6M	Sell	97,048 -5,264	-5%	-$702K	0.26%	110
2024 Q2	$14.6M	Buy	102,312 +8,135	+9%	+$1.08M	0.34%	86
2024 Q1	$12.1M	Buy	94,177 +41,082	+77%	+$4.89M	0.28%	104
2023 Q4	$5.49M	Buy	+53,095	New	+$5.25M	0.13%	196

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Sit Investment Associates's NVO Position: Q1 2026 in Review

Sit Investment Associates sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 24,650 shares — an estimated $1.25M sold.

Sit Investment Associates first reported a position in NVO in Q4 2023 and held it in 9 quarters. The position peaked at $14.6M in Q2 2024. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Sit Investment Associates reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
Sit Investment Associates sold 24,650 Novo Nordisk shares in Q1 2026, an estimated $1.25M.
Sit Investment Associates first reported a position in Novo Nordisk in Q4 2023 and held it in 9 quarters.
Sit Investment Associates's Novo Nordisk position peaked at $14.6M in Q2 2024.
1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Sit Investment Associates's 13F filing for Q1 2026, filed 13 May 2026.